Promising DMD drug SAT-3247 tested for Long-Term safety and muscle benefits
NCT ID NCT06867107
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This study looks at the long-term safety and effects of the drug SAT-3247 in people with Duchenne muscular dystrophy (DMD) who have taken it before. Up to 10 participants will take the drug for about 12 months total. Researchers will check for side effects and measure changes in muscle fat and strength.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
St. Vincent Hospital
Melbourne, Victoria, Australia
-
The Royal Children's Hospital
Melbourne, Victoria, 3052, Australia
Conditions
Explore the condition pages connected to this study.